GlassScriptPhysician profile
Obiora Anyoku
NPI 1225093180
$830.43
in general payments reported to CMS, 2019-2025
13 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.72 · 2020: $38.56 · 2024: $232 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.69 | 2024-2025 | Ozempic, Rybelsus |
| Opko Pharmaceuticals, LLC | $114.03 | 2024-2025 | Rayaldee |
| Lilly USA, LLC | $94.77 | 2019-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $79.91 | 2020-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $68.01 | 2024-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.57 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $54.33 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $45.94 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $24.22 | 2025 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $22.83 | 2025 | Loreev Xr |
| Pfizer INC. | $22.58 | 2025 | |
| Bridgebio Pharma, INC. | $20.96 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $16.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obiora Anyoku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.